However, heterogeneity is a hallmark of in vivo cancer, and it will be possible, in the future, to map areas of weakened cell-cell adhesions or drug response in the KPC model by examining E-cadherin mobilization in the center versus the invasive front of the tumor (Serrels et al., 2009). This evidence concerns the gene CDH1 and neoplasm.